Close Menu

At In the Pipeline, Derek Lowe asks in which fields people would consider starting a small drug company. He writes that oncology would have been a good choice a decade ago and that going into cardiovascular disease and metabolic disorders doesn’t make much sense, unless you've been sitting on a golden egg. Alzheimer's disease, he says, is an under-served market, adding that "it's unserved for a lot of damned good reasons. The same goes for a number of other CNS indications.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.